Arch Therapeutics, Inc.
Company Snapshot: Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.
- Jul 20 2018 Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors
- Jun 29 2018 Arch Therapeutics, Inc. $4.5 Million Registered Direct Offering
- Jun 26 2018 Arch Therapeutics Provides Skin Sensitization Study Status Update
- Jun 15 2018 Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study